Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024
BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the sale of the first SRT-100 Vision™ (IG-SRT) system in Asia, to Far Eastern Memorial Hospital in Taiwan. The hospital, which has more than 1,000 beds, is one of the largest private hospitals in Taiwan.
Far Eastern Memorial Hospital also plans to publish research on possible new indications for the SRT-100 Vision (IG-SRT), which may be instrumental in the support of label expansion beyond non-melanoma skin cancer and keloids worldwide.
“We are delighted to sell the first SRT-100 Vision system in Asia, in particular to such a prominent hospital as Far Eastern Memorial,” said Benson Suen, Sensus Healthcare’s Vice President of Internation Sales. “We are optimistic this sale will open the door to additional sales of our premium-featured Vision system in the region, including across China. In addition, Far Eastern Memorial Hospital will serve as the Vision reference center and is expected to help us promote awareness of the system.”
The SRT-100 Vision (IG-SRT), a Sensus Healthcare exclusive, utilizes image-guided ultrasound. Sentinel™ technology, which contains HIPAA-compliant software with clinical, billing and asset-management utility also may be available in this system. In addition, last year Sensus introduced an important new and improved high-resolution ultrasound technology to provide See & Treat capability. This leads to excellent clinical outcomes because the physician can see the impact of each treatment on the lesion, and lesion resolution following treatment.
First Quarter Conference Call and Webcast
Sensus reminds investors that management will be hosting a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss financial results for the first quarter of 2024. In addition, management will provide a business update and review recent and upcoming milestones.
Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable to pre-register may access the conference call by dialing, 1-844-481-2811 (U.S. and Canada Toll Free) or 1-412-317-0676 (International). Please direct the operator to be connected to the Sensus Healthcare conference call.
The call will be webcast live and can be accessed at this link, which also may be found in the Investor Relations section of the Company’s website at www.sensushealthcare.com.
Following the conclusion of the conference call, a telephone replay will be available until June 9th, and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free), or 412-317-0088 (International). At the system prompt, dial the replay code – 9785929 – followed by the # sign. Playback will automatically begin. An archived webcast of the call will also be available in the Investor Relations section of the Company’s website for a period of time.
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for
skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology,
the company provides healthcare providers with a highly effective, patient-centric treatment platform.
With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are
safe, precise, and adaptable to a variety of clinical settings.
For more information, visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to maintain profitability; our ability to sell the number of SRT units we anticipate for the balance of 2024; the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the performance of the Company’s information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
To date, we do not expect that the Middle East conflict, the Russian invasion of Ukraine and global geopolitical uncertainty have had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable
Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
